Pharmaceutical Companies, Government and...

Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry ... Show More

The third Green Templeton Lecture 2009 explores how, by harnessing innovation to meet unmet medical needs, pharma companies can deliver significant value to patients, payers and shareholders. The Green Templeton Lectures 2009 explored the theme 'Addicted to Big Pharma? Reconcilin ... Show More

Tilli Tansey, Professor of History of Modern Medical Sciences, University College London traces the evolution of the modern pharmaceutical industry from the mid nineteenth century to the final decades of the twentieth century. The strong focus on British companies is not exclusiv ... Show More

China is fast becoming a major player in the global pharmaceutical and biotech industries. Once focused primarily on generic and me-too drugs, Chinese companies are now making headlines with innovative breakthroughs in oncology and gene therapy. Foreign investors are taking notic ... Show More

In an age where pharmacy is a global industry, stigma and medicine are now in the position where they are the co-constructors of illness on one hand and mutually exclusive players on the other. Professor Sonia Ryang (Anthropology and International Studies, University of Iowa) ext ... Show More

<p>Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.</p><p>Together, they discuss the transformative power of drugs in changing human health—and history. They also reflect on the evolution of the drug discovery p ... Show More

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ... Show More

"Pharmaceutical Breakthroughs: The Cutting Edge of Biotechnology" - In this episode, we dive deep into the revolutionary world of biotechnology and its transformative impact on pharmaceuticals. Discover how cutting-edge innovations are reshaping drug development, accelerating vac ... Show More

In this episode of "Driving Digital in Biopharma," host Tom Lehmann welcomes Morrey Atkinson, the Chief Technology and Operations Officer at Vertex Pharmaceuticals. With a rich background in process development and manufacturing within the pharmaceutical industry, Morrey shares h ... Show More

<p>We explore the science, scalability, and (of course) economics surrounding the global vaccine race. Guests include the chief medical officer of the first U.S. firm to go to Phase 3 trials with a vaccine candidate; a former F.D.A. commissioner who’s been warning of a pandemic f ... Show More

Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How ... Show More

During the pandemic, the world witnessed how fast medicine can advance with an abundance of cash and collaboration. Is progress at this speed and cost sustainable? Sandra Kanthal asks if drug development is something which should still take decades, or have we learned how to perm ... Show More